Journal article

Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol

A Mooranian, R Negrulj, N Chen-Tan, HS Al-Sallami, Z Fang, TK Mukkur, M Mikov, S Golocorbin-Kon, M Fakhoury, GF Watts, V Matthews, F Arfuso, H Al-Salami

Drug Design Development and Therapy | DOVE MEDICAL PRESS LTD | Published : 2014

Abstract

Introduction: In previous studies, we successfully designed complex multicompartmental microcapsules as a platform for the oral targeted delivery of lipophilic drugs in type 2 diabetes (T2D). Probucol (PB) is an antihyperlipidemic and antioxidant drug with the potential to show benefits in T2D. We aimed to create a novel microencapsulated formulation of PB and to examine the shape, size, and chemical, thermal, and rheological properties of these microcapsules in vitro.Method: Microencapsulation was carried out using the Büchi-based microencapsulating system developed in our laboratory. Using the polymer, sodium alginate (SA), empty (control, SA) and loaded (test, PB-SA) microcapsules were pr..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

The authors acknowledge the Curtin Health Innovation Research Institute at Curtin University and the Curtin-seeding grant for their support and also acknowledge the use of equipment and the scientific and technical assistance of the Curtin University Electron Microscope Facility, which has been partially funded by the university, state, and commonwealth governments. The authors also acknowledge the Pharmaceutical Technology Laboratory for their valuable assistance (Curtin School of Pharmacy).